News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
880,569 Results
Type
Article (88603)
Company Profile (815)
Press Release (791118)
Multimedia
Podcasts (228)
Webinars (34)
Section
Business (233517)
Career Advice (4158)
Deals (39952)
Drug Delivery (172)
Drug Development (91619)
Employer Resources (207)
FDA (18523)
Job Trends (17472)
News (398542)
Policy (40012)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (5)
Academia (3043)
Academic (2)
Accelerated approval (49)
Adcomms (39)
Allergies (184)
Alliances (56987)
ALS (225)
Alzheimer's disease (1931)
Antibody-drug conjugate (ADC) (497)
Approvals (18808)
Artificial intelligence (810)
Autoimmune disease (310)
Automation (59)
Bankruptcy (407)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (237)
Biotechnology (486)
Bladder cancer (196)
Brain cancer (80)
Breast cancer (792)
Cancer (6153)
Cardiovascular disease (528)
Career advice (3590)
Career pathing (48)
CAR-T (362)
CDC (75)
Celiac Disease (3)
Cell therapy (1010)
Cervical cancer (49)
Clinical research (78420)
Collaboration (2249)
Company closure (8)
Compensation (1426)
Complete response letters (101)
COVID-19 (3029)
CRISPR (119)
C-suite (1193)
Cystic fibrosis (163)
Data (7991)
Decentralized trials (3)
Denatured (86)
Depression (186)
Dermatology (86)
Diabetes (633)
Diagnostics (7507)
Digital health (61)
Diversity (13)
Diversity, equity & inclusion (49)
Drug discovery (394)
Drug pricing (244)
Drug shortages (39)
Duchenne muscular dystrophy (302)
Earnings (102195)
Editorial (77)
Employer branding (25)
Employer resources (174)
Events (137565)
Executive appointments (1159)
FDA (22395)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (15)
Frontotemporal dementia (35)
Funding (1843)
Gene editing (261)
Generative AI (86)
Gene therapy (821)
GLP-1 (1244)
Government (5543)
Grass and pollen (8)
Guidances (413)
Healthcare (21089)
HIV (89)
Huntington's disease (62)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (101)
Immunology and inflammation (345)
Immuno-oncology (103)
Indications (189)
Infectious disease (3403)
Inflammatory bowel disease (240)
Inflation Reduction Act (17)
Influenza (147)
Intellectual property (300)
Interviews (820)
IPO (17991)
IRA (61)
Job creations (5205)
Job search strategy (2870)
JPM (73)
Kidney cancer (22)
Labor market (111)
Layoffs (678)
Leadership (49)
Legal (10171)
Liver cancer (107)
Longevity (35)
Lung cancer (806)
Lymphoma (437)
Machine learning (63)
Management (66)
Manufacturing (1137)
MASH (202)
Medical device (15226)
Medtech (15350)
Mergers & acquisitions (23215)
Metabolic disorders (1685)
mRNA (247)
Multiple sclerosis (197)
NASH (24)
Neurodegenerative disease (470)
Neuropsychiatric disorders (125)
Neuroscience (3579)
Neurotech (2)
NextGen: Class of 2026 (7713)
Non-profit (5137)
Now hiring (78)
Obesity (819)
Opinion (366)
Ovarian cancer (227)
Pain (273)
Pancreatic cancer (310)
Parkinson's disease (387)
Partnered (39)
Patents (626)
Patient recruitment (700)
Peanut (67)
People (67742)
Pharmaceutical (138)
Pharmacy benefit managers (36)
Phase 1 (24229)
Phase 2 (34061)
Phase 3 (25622)
Pipeline (8714)
Policy (385)
Postmarket research (3558)
Preclinical (10910)
Press Release (72)
Prostate cancer (312)
Psychedelics (68)
Radiopharmaceuticals (351)
Rare diseases (1195)
Real estate (7457)
Recruiting (81)
Regulatory (30091)
Reports (77)
Research institute (2763)
Resumes & cover letters (653)
Rett syndrome (39)
RNA editing (27)
RSV (98)
Schizophrenia (191)
Series A (313)
Series B (224)
Service/supplier (30)
Sickle cell disease (121)
Special edition (31)
Spinal muscular atrophy (188)
Sponsored (55)
Startups (4363)
State (2)
Stomach cancer (21)
Supply chain (139)
Tariffs (104)
The Weekly (139)
Vaccines (1266)
Venture capital (122)
Weight loss (564)
Women's health (131)
Worklife (24)
Date
Today (224)
Last 7 days (981)
Last 30 days (3672)
Last 365 days (33114)
2026 (12918)
2025 (33226)
2024 (38124)
2023 (42564)
2022 (53928)
2021 (58721)
2020 (57664)
2019 (51336)
2018 (39119)
2017 (37189)
2016 (38329)
2015 (44432)
2014 (39672)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1296)
Alabama (100)
Alaska (7)
Arizona (390)
Arkansas (16)
Asia (52079)
Australia (9159)
California (13696)
Canada (3844)
China (1442)
Colorado (592)
Connecticut (608)
Delaware (420)
Europe (120079)
Florida (2027)
Georgia (446)
Hawaii (4)
Idaho (69)
Illinois (1173)
India (97)
Indiana (637)
Iowa (25)
Japan (550)
Kansas (140)
Kentucky (56)
Louisiana (46)
Maine (88)
Maryland (1677)
Massachusetts (10014)
Michigan (409)
Minnesota (762)
Mississippi (7)
Missouri (160)
Montana (37)
Nebraska (30)
Nevada (147)
New Hampshire (92)
New Jersey (3648)
New Mexico (34)
New York (3594)
North Carolina (1857)
North Dakota (11)
Northern California (6754)
Ohio (426)
Oklahoma (26)
Oregon (55)
Pennsylvania (2720)
Puerto Rico (30)
Rhode Island (53)
South America (1668)
South Carolina (87)
South Dakota (2)
Southern California (5357)
Tennessee (217)
Texas (2221)
United States (49102)
Utah (410)
Vermont (1)
Virginia (354)
Washington D.C. (88)
Washington State (1130)
West Virginia (4)
Wisconsin (152)
Wyoming (2)
There are 880,569 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using Its Proprietary Botanical Synthesis Platform
Source plant is widely regarded as one of the most valuable fragrance raw materials in the world Stage 2 contract follows successful Stage 1 completion in March 2026
May 12, 2026
·
4 min read
Press Releases
Zenith Capital Corp. Amends Promissory Notes
May 12, 2026
·
6 min read
Press Releases
DIMERx Preclinical Data Confirms DMX-101 Non-Addictive Profile: No Reinforcement, No Dependence
Key Regulatory Benchmark Met, Differentiating DMX-101 from Traditional Opioid Analgesics Late-Breaking Results to be Presented at CPDD 2026 Annual Meeting
May 12, 2026
·
5 min read
Press Releases
Phio Pharmaceuticals Announces “Innovations in Skin Cancer Treatment and Prevention” in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026
Live virtual fireside chat — investors, advisors, and life sciences analysts invited to attend Featuring Dermatologist Mary Spellman, M.D., with Phio CEO Robert Bitterman and Force Family Office CEO Steven Saltzstein
May 12, 2026
·
5 min read
Press Releases
U.S. Biopharmaceutical Third-party Logistics Market to Hit USD 118.06 Bn by 2035
May 12, 2026
·
1 min read
Press Releases
Fusion Biopsy Market Size Worth USD 803.50 Mn by 2035 Amid Rising Adoption of Precision Prostate Cancer Diagnostics
May 12, 2026
·
1 min read
FDA
FDA’s Makary to resign after Secretary Kennedy signs off
FDA Commissioner Marty Makary intends to resign on Tuesday, according to several sources. This report follows a tumultuous 13-month tenure in which Makary oversaw the controversial rejections of several rare disease drugs and “predictable volatility” within the agency.
May 12, 2026
·
4 min read
·
Annalee Armstrong
Press Releases
EktaH Shows ~50% Reduction in Post-GLP-1 Weight Rebound with Novel Obesity Treatment and Reports Positive Phase I Data
· First-in-class oral mechanism triggers natural satiety hormones, addressing key limitations of GLP-1 therapies · Phase I data demonstrate fat mass reduction, preservation of lean mass, 80% responder rate, and no serious adverse events
May 12, 2026
·
1 min read
Press Releases
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
May 12, 2026
·
11 min read
Press Releases
Evergreen Nephrology Appoints Eugenia Timm as Chief Operating Officer
May 12, 2026
·
2 min read
1 of 88,057
Next
